Literature DB >> 4556618

Treatment of Parkinson's disease with amantadine and L-Dopa.

U K Rinne, V Sonninen, T Siirtola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4556618     DOI： 10.1159/000114429

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  4 in total

1.  Plasma growth hormone and insulin response to levodopa and amantadine.

Authors:  O Kytömäki; R Nousiainen; A Pekkarinen; U K Rinne; M Viljanen
Journal:  J Neural Transm       Date:  1973       Impact factor: 3.575

2.  Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.

Authors:  M Brenner; A Haass; P Jacobi; K Schimrigk
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

Review 3.  Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.

Authors:  James W Bales; Amy K Wagner; Anthony E Kline; C Edward Dixon
Journal:  Neurosci Biobehav Rev       Date:  2009-04-01       Impact factor: 8.989

Review 4.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.